Cardiac cell proliferation by administering inhibitors of SAV1, NF2, MOB1 and/or mutant SRF
Disclosed are DsiRNA inhibitors for the genes encoding SAV1, NF2 and MOB1, which cause proliferation of cardiomyocytes on administration to a mammal. The DsiRNA inhibitors can also be administered with a mutant SRF (153-A3) or an mRNA encoding it, and/or Yap5SA (a Yap mutant) or an encoding mRNA, which enhance the proliferative effect on cardiomyocytes. Mutant SRF (153-A3) with Yap5SA alone also induce myocyte replication.
1 . A method of inducing replication of cardiac cells in a mammal, comprising:
administering to the mammal one or more of the following complementary DsiRNA pairs wherein the complementary DsiRNA pairs target the Mob1 gene and are selected from the group consisting of:
SEQ ID NOS: 43 & 44; SEQ ID NOS: 45 & 46 and SEQ ID NOS: 47 & 48.
2 . The method of claim 1 wherein the mammal is a human and the complementary DsiRNA pairs are selected from the group consisting of: SEQ ID NOS: 43 & 44; SEQ ID NOS: 45 & 46 and SEQ ID NOS: 47 & 48.
3 . The method of claim 1 wherein the cardiac cells are cardiomyocytes.
4 . The method of claim 1 , wherein the administering is by oral administration, inhalation, subcutaneous administration, intravenous administration, intraperitoneal administration, intramuscular administration, intrathecal injection, intra-articular administration, topical administration, central administration, peripheral administration, aerosol-based administration, nasal administration, transmucosal administration, transdermal administration, parenteral administration, or combinations thereof.
5 . The composition of claim 1 , wherein the composition comprises a delivery vehicle.
6 . The composition of claim 5 , wherein the delivery vehicle comprises liposomes.